Encore Presentation: Therapeutic Evolution in mHSPC Analyzing Emerging Combinations and Outcomes CME Friday, February 27, 2026 | 10:00 AM - 11:00 AM ET Virtual

https://na.eventscloud.com/website/92668/ Make confident, evidence-based treatment decisions for your patients with metastatic hormone-sensitive prostate cancer (mHSPC). The treatment landscape for mHSPC is quickly evolving, with a growing number of therapy options. Recent trials demonstrate that intensifying androgen deprivation therapy (ADT) with second-generation anti-androgens ± chemotherapy improves survival and delays progression to castration-resistant disease. In this 60-minute discussion, our expert panel will explore ways to apply selection criteria for doublet vs triplet therapy, navigate sequencing decisions, and other strategies for maximizing survival and optimizing quality of life for patients with mHSPC. Not an official event of the 2026 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.